Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
104.23
+0.41 (0.39%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Axsome Therapeutics Employees
Axsome Therapeutics had 683 employees as of December 31, 2024. The number of employees increased by 138 or 25.32% compared to the previous year.
Employees
683
Change (1Y)
138
Growth (1Y)
25.32%
Revenue / Employee
$564,704
Profits / Employee
-$420,521
Market Cap
5.08B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
AXSM News
- 2 days ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 16 days ago - Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 - GlobeNewsWire
- 20 days ago - Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting - GlobeNewsWire
- 23 days ago - Axsome's depression treatment fails to meet main goal of late-stage study - Reuters
- 4 weeks ago - Axsome Therapeutics' ADHD drug meets main goal in late-stage study - Reuters
- 4 weeks ago - Axsome: The Alzheimer's Agitation Program For AXS-05 - Seeking Alpha
- 2 months ago - Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs - Benzinga
- 2 months ago - Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering - Seeking Alpha